Bernstein, Barry M.,Dutta, Sandeep,Liu, Wei,Podsadecki, Thomas J.,Campbell, Andrew L.,Menon, Rajeev M.,Lin, Chih-Wei,Wang, Tianli,Awni, Walid M.,Mensing, Sven
申请号：
HRP20171898
公开号：
HRP20171898T1
申请日:
2017.12.06
申请国别(地区):
HR
年份:
2018
代理人:
摘要：
The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of interferon, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.
